Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs

• Published in: Dialogues in clinical neuroscience 2016-09, Vol.18 (3), p.313-322
• Main Author: Eap, Chin B.
• Format: Article
• Language: English
• Subjects: antidepressant; antipsychotic; Cytochrome P-450 Enzyme System - genetics; Cytochrome P-450 Enzyme System - metabolism; cytochrome P450; Humans; Mental Disorders - drug therapy; Mental Disorders - genetics; pharmacodynamic; pharmacogenetic; pharmacogenomic; Pharmacogenomic Testing; pharmacokinetic; Pharmacological Aspects; Practice Patterns, Physicians; Precision Medicine; psychiatry; psychotropic drug; Psychotropic Drugs - adverse effects; Psychotropic Drugs - metabolism; Psychotropic Drugs - pharmacokinetics; Psychotropic Drugs - therapeutic use; therapeutic drug monitoring
• ISSN: 1958-5969; 1294-8322; 1958-5969
• DOI: 10.31887/DCNS.2016.18.3/ceap

The use of pharmacogenetic tests was already being proposed in psychiatry in the early 2000s because genetic factors were known to influence drug pharmacokinetics and pharmacodynamics. However, sufficient levels of evidence to justify routine use have been achieved for only a few tests (eg, major histocompatibility complex, class I, B, allele 1502 [HLA-B*1502] for carbamazepine in epilepsy and bipolar disorders); many findings are too preliminary or, when replicated, of low clinical relevance because of a small effect size. Although drug selection and dose adaptation according to cytochrome P450 genotypes are sound, a large number of patients need to be genotyped in order to prevent one case of severe side effect and/or nonresponse. The decrease in cost for genetic analysis shifts the cost: benefit ratio toward increasing use of pharmacogenetic tests. However, they have to be combined with careful clinical evaluations and other tools (eg, therapeutic drug monitoring and phenotyping) to contribute to the general aim of providing the best care for psychiatric patients.